The Six-Year Truth: Methylprednisolone Is Not a Steroid — And That Is What Rewrites Ruti Aga's Case

September 10. One date, one name, and one number — six years. In the Ruti Aga case, the figure dominating headlines is the same figure least understood. Six years. Break that number open and it splits into two and four — two years for presence, four years for corrupting the evidence. Two years for something that may have been medicine. Four years for a document that was not.

I have read the marathon record book like a crime scene for years. Every number has a source, and every source has an agenda. In this case, the source made an error that changes what the entire case means.

Context: the drug that got mislabelled

Start with the fact the report got wrong. Methylprednisolone was called a "prohibited steroid" and described as classed performance-enhancing by WADA. That is imprecise and misleading. Methylprednisolone is a glucocorticoid — WADA Prohibited List class S9 — not an anabolic steroid (S1).

Why does the distinction matter? Because S9 substances are prohibited in-competition only, and only by injection, oral or rectal routes. A therapeutic knee injection given out-of-competition is entirely legal. It becomes a violation only if residues are present in a sample collected in-competition.

That technicality was the foundation of an entire defence. And the media erased it.

Now the architecture of the event. A half marathon in China in March. Aga won it. The report carries no mark — no time, no splits, no field quality. I cannot draw a single performance conclusion, because the data does not exist. "Won" tells us only that this was a race with a World Athletics Label-tier elite women's field and in-competition testing in force. That is all.

What survives is the 2026 Tokyo Marathon title. The violation is anchored to that March race. Absent proof of earlier use, results before that date — Tokyo included — are not automatically annulled. The report never states the disqualification scope, and that is its largest hole.

Core: three verification failures, one knee

The knee injury. This is the case's true entry point. Chronic knee pathology is a known load-bearing failure mode in distance running. Intra-articular methylprednisolone for marathoners is standard sports-medicine practice. That medical plausibility is exactly what makes it dangerous — because a genuinely documented treatment would have been defended with the real records.

But the documents were not real.

Three verification failures, one after another. First: the prescription came from a clinic that did not exist. Second: the "doctor" was a family member with no medical registration. Third: that person claimed to have used an "old prescription pad from a former workplace" — and the clinic publicly disowned it.

This is not a filing error. It is the signature of an athlete operating without a credentialed team physician. The TUE infrastructure was zero. A properly managed runner with a documented knee injection either holds a Therapeutic Use Exemption or observes the route-specific washout period. Neither happened here. A forged prescription was manufactured instead.

And that is where the real arithmetic hides. Two years for the presence violation. That is consistent with a Specified Substance finding where intent was not proven. Four years for tampering — the Code's standard sanction. Add them: six years.

The arithmetic tells us the panel rejected the no-significant-fault mitigation that would otherwise have reduced the presence sanction. The four-year tampering ban is not an independent coincidence — it is the most frequently charged second offence in the AIU's East African road-racing caseload.

Backdating to September 10 is a procedural benefit, not a reduction. Provisional suspension time counts against the ban. In real terms the athlete gained nothing from it.

Now the direct career calculation. Age 32. Return age after six years: roughly 38. Ethiopian women's marathon depth is so extreme that even a 2:18-class runner is not automatically selectable. A 38-year-old returnee with a doping record is effectively unselectable. This sanction is a lifetime ban for elite purposes. And it must be stated plainly — the factor that converted a likely two-year absence into six years was not the substance. It was the document.

Contrarian: the defence existed, and the athlete burned it herself

Here is the angle nobody is writing.

The media misclassified the substance — calling it a steroid when it is a glucocorticoid. That pushed the case into comparison with anabolic-steroid cases, which is technically wrong. But the real damage is this: the misclassification concealed that the athlete had a legitimate defence. Timing, route, medical necessity — all three were arguable.

She destroyed that defence herself. By forging the prescription.

The paradox sits right there: forged documentation is itself circumstantial evidence of concealment intent. Yet it did not escalate the presence sanction — it only added a separate one. The panel weighed the two charges separately, which signals the presence violation was treated as non-intentional while the tampering was treated as fully culpable.

The family-member "doctor" is an aggravating, not mitigating, fact. But one question is left unanswered: was the agent or management investigated? The AIU statement names only the family member. The entire cost was placed on one individual, while the structure belongs to the same ecology the athlete races inside.

And the larger point, which will be cited from both directions: a six-year ban for a substance with no proven endurance benefit. That figure will be used as evidence of AIU rigour, and as evidence of disproportionate enforcement against African road runners. Both readings flow from the same fact. That is why the fact needs to be clean.

For the benchmark: Aga's three World Marathon Majors second places were commercial-tier results, not championship conversions. The ban's effect on Ethiopia's medal capacity is roughly zero. The sporting map did not change. The governance map did.

Takeaway: the next lever is documentary

China's label-race circuit is now a high-scrutiny zone. Large appearance-fee budgets, deep East African elite fields, and AIU testing — three forces colliding in the same race. The appearance-fee economy and the testing economy are facing off, and the collision is now showing up in results.

The next question is not who gets caught. The question is whether the enforcement frontier has shifted from "detection" to "document verification." Aga's case is not an outlier — it belongs to a recognisable family of cases where an initial violation is compounded by a fabricated explanation. As long as informal medical networks serve multiple athletes inside the same training clusters, similarly profiled cases will keep arriving.

The 2026 Tokyo title stays in the record book. Everything else — the time, the name, and the six years — sits on the decision table. And one question that should be asked of every race director: next time a runner lines up with a knee injection, who checks the paperwork — the athlete, the agent, or the testing agency?